The estimated Net Worth of Frank Mottola is at least $428 Thousand dollars as of 28 February 2024. Mr. Mottola owns over 990 units of Supernus Pharmaceuticals Inc stock worth over $256,068 and over the last 5 years he sold SUPN stock worth over $172,032. In addition, he makes $0 as Senior Vice President, Quality, and GMP Operations and Information Technology at Supernus Pharmaceuticals Inc.
Sign up
Mr. Mottola SUPN stock SEC Form 4 insiders trading
Frank has made over 4 trades of the Supernus Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 990 units of SUPN stock worth $30,769 on 28 February 2024.
The largest trade he's ever made was selling 4,780 units of Supernus Pharmaceuticals Inc stock on 14 March 2023 worth over $172,032. On average, Frank trades about 773 units every 31 days since 2020. As of 28 February 2024 he still owns at least 8,239 units of Supernus Pharmaceuticals Inc stock.
You can see the complete history of Mr. Mottola stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frank Mottola biography
Frank Mottola serves as Senior Vice President, Quality, GMP Operations and Information Technology of the Company. Prior to that, Mr. Mottola was Vice President of Quality, GMP Operations and Information Technology from 2017 to 2020. From 2014 to 2017, he served as Vice President of Quality and GMP Operations. Mr. Mottola served as Director of Quality from 2005 to 2013. Prior to 2005, Mr. Mottola was the Director of Quality at Able Laboratories and previously held various positions at Ortho Clinical Diagnostics (a Johnson & Johnson company). He has 24 years of experience in the pharmaceutical industry and holds Bachelor of Science degrees in Biology and Business Administration from Rutgers University and Walden University, respectively.
How old is Frank Mottola?
Frank Mottola is 48, he's been the Senior Vice President, Quality, and GMP Operations and Information Technology of Supernus Pharmaceuticals Inc since 2020. There are 16 older and no younger executives at Supernus Pharmaceuticals Inc. The oldest executive at Supernus Pharmaceuticals Inc is John Siebert, 80, who is the Independent Director.
What's Frank Mottola's mailing address?
Frank's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.
Insiders trading at Supernus Pharmaceuticals Inc
Over the last 13 years, insiders at Supernus Pharmaceuticals Inc have traded over $37,265,765 worth of Supernus Pharmaceuticals Inc stock and bought 16,600,700 units worth $83,216,588 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Supernus Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $4,263,834. The most recent stock trade was executed by Jack A. Khattar on 3 September 2024, trading 21,000 units of SUPN stock currently worth $652,680.
What does Supernus Pharmaceuticals Inc do?
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
What does Supernus Pharmaceuticals Inc's logo look like?
Complete history of Mr. Mottola stock trades at Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals Inc executives and stock owners
Supernus Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Jack Khattar,
President, Chief Executive Officer, Secretary, Director -
Jack A. Khattar,
Founder, Pres, CEO, Sec. & Director -
Stefan Schwabe,
Executive Vice President - Research and Development, Chief Medical Officer -
Padmanabh Bhatt,
Senior Vice President - Intellectual Property, Chief Scientific Officer -
Tami Martin,
Senior Vice President - Regulatory Affairs -
Dr. Padmanabh P. Bhatt,
Chief Scientific Officer & Sr. VP of Intellectual Property -
Tami T. Martin,
Sr. VP of Regulatory Affairs -
Charles Newhall,
Independent Chairman of the Board -
Frederick Hudson,
Independent Director -
John Siebert,
Independent Director -
Georges Gemayel,
Independent Director -
Carrolee Barlow,
Independent Director -
Frank Mottola,
Senior Vice President, Quality, GMP Operations and Information Technology -
James Kelly,
Chief Financial Officer, Executive Vice President -
Jeff Bozick,
Sr. VP of Supply Chain -
Frank Mottola,
Sr. VP of Quality, GMP Operations & Information Technology -
Kevin T. Anderson,
Compliance Officer -
Timothy C. Dec,
Sr. VP & CFO -
Dr. Jonathan Rubin,
Sr. VP & Chief Medical Officer -
Dr. Bryan A. Roecklein,
VP of Corp. Devel. -
Taylor Raiford,
VP of Sales -
Dr. Todd Horich M.B.A., Ph.D.,
VP of Marketing -
William A. Nuerge,
Director -
M James Barrett,
Director -
Victor Vaughn,
Sr. VP of Sales -
Krishna Kittu Kolluri,
10% owner -
Advisors Llcisaly Samuel Do...,
-
Partners 11 Lp Nea,
10% owner -
Forest Baskett,
10% owner -
Michael Bigham,
Director -
Peter J Barris,
10% owner -
Enterprise Associates 11 Lp...,
10% owner -
Scott D Sandell,
10% owner -
Jones W. Bryan,
VP of Business Development -
Management Ltd Abingworth,
10% owner -
Advisors Llcorbimed Capital...,
-
Michael B Sheffery,
Director -
Gregory S Patrick,
Sr. VP Chief Financial Officer -
Jonathan Rubin,
SVP, Chief Medical Officer -
Timothy C Dec,
Senior Vice-President & CFO -
Bethany Sensenig,
Director